Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.
A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...
EMERYVILLE, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary ...
Find how Circularization for High-throughput Analysis of Nuclease Genome-wide Effects by Sequencing Base Editors ...
Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development of novel gene editing therapies This new Pin-point ...
Beijing Zhongke Journal Publising Co. Ltd. This study is led by Professor Lanqin Xia (Institute of Crop Sciences, Chinese Academy of Agricultural Sciences, Beijing, China). The authors isolated a rice ...
Cytosine and adenine base editors (CBEs and ABEs) are promising new tools for achieving the precise genetic changes required for disease treatment and trait improvement. However, genome-wide and ...
X-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder characterized by high susceptibility to infections that results from genetic mutations in the cytochrome b-245 beta chain ...
Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly ...
“Base editors are powerful gene editing tools that are able to modify genes through single nucleotide changes, including multiplexed gene editing applications without risk of translocations. Our ABEs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback